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Abstract
Objective: To identify clinical characteristics associated with internal neurofibromas in children with NF1, as a
means of ensuring the early identification of patients at high risk for malignant peripheral nerve-sheath tumors
developed from preexisting internal neurofibromas.
Patients and methods: We used data from two NF1 populations, in France and North America, respectively.
The French database comprised 1083 patients meeting NIH diagnostic criteria for NF1 and the
Neurofibromatosis Institute Database of North America comprised 703 patients. Patients younger than
17 years of age were eligible for our study if they had been evaluated for internal neurofibromas using
computed tomography and/or magnetic resonance imaging. Clinical characteristics associated with internal
neurofibromas by univariate analysis (P≤ 0.15) were entered into a multiple logistic regression model after
checking for potential interactions and confounding. Multiple imputation was used for missing values.
Results: Among the 746 children in the two databases, 357 (48%) met our inclusion criteria. Their mean age
was 7.7 ± 5.0 years and there were 192 (53.8%) males. Internal neurofibromas were present in 35 (9.8%)
patients. Internal neurofibromas developed earlier in females than in males and their prevalence increased
during adolescence. Factors independently associated with internal neurofibromas were age (OR = 1.16
[1.07-1.27]), xanthogranulomas (OR = 5.85 [2.18-15.89]) and presence of both subcutaneous and plexiform
neurofibromas (OR = 6.80 [1.52-30.44]).
Conclusions: Several easily recognizable clinical characteristics indicate a high risk of internal neurofibromas
in children with NF1 and, therefore, a need for very close monitoring.
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Background
Neurofibromatosis-1 (NF1 [MIM 162200]) is a common
autosomal dominant disorder with an incidence of 1 in
2500–3000 births and a prevalence of 1 in 4000 [1]. NF1
is associated with increased morbidity and mortality
rates [2,3]. In spite of tremendous progress in under-
standing and treating NF1, there continues to be incon-
sistency, if not confusion about the various types of
neurofibromas. Our interest in this article is to sensitize
clinicians to NF1 neurofibromas that are not obvious by
inspection and/or palpation of the skin. That is, the
focus is on internal neurofibromas. An internal neuro-
fibroma simply is a neurofibroma that is not appreciated
by physical examination. Part of the problem is that
some neurofibromas that may have internal components
may also be apparent externally. In particular, both the
large diffuse plexiform neurofibroma and the large
nodular plexiform neurofibroma, as described by Riccardi
[4], corresponding to Masson’s diffuse neurofibroma and
encapsulated neurofibroma, respectively, as utilized by
Tucker and coworkers [5,6], can have both external
and internal components. In the present article we
are reserving the term, internal neurofibroma, for
those neurofibromas not having an apparent external
component. By definition, both cutaneous neuro-
fibromas and subcutaneous neurofibromas are
excluded from being internal neurofibromas. Most
specifically, the term, plexiform neurofibroma, does
not on its own afford distinction from or inclusion
in what we are specifying here as an internal
neurofibroma.
Internal neurofibromas are among the main causes
of life-threatening events in patients with NF1 [4,7].
Ten percent of internal neurofibromas undergo
transformation to malignant peripheral nerve-sheath
tumors (MPNSTs) [8], a leading cause of death in
adults with NF1 [2,3]. Clinical indicators of MPNST
are persistent or increasing pain, enlargement of the
tumor, and neurological deficiencies [9]. The diagno-
sis is often delayed, especially for deep diffuse plexi-
form or internal neurofibromas as imaging studies
are not performed routinely as part of the follow-up
of patients with NF1 [10] but instead are ordered
only as clinically indicated [11]. The mean age at
diagnosis of MPNST is younger in patients with NF1
than in unaffected individuals [8,12-14]. MPNSTs
may develop before 30 years of age [8,12] and even
in childhood [13]. Moreover internal neurofibromas
grow faster in young patients [15]. In previous work,
we developed a simple scoring system (the NF1Score)
that accurately predicted the presence of internal
neurofibromas at risk for transformation to MPNST
in adults with NF1 [16]. Four characteristics were
independently associated with internal neurofibromas:
presence of subcutaneous neurofibromas, fewer than
6 café-au-lait spots, absence of cutaneous neurofibro-
mas, and age ≤30 years. However, the NF1Score was
developed in patients aged 17 years or older. Conse-
quently, a specific study was needed in pediatric
patients. The clinical expression of NF1 varies across
the life span in a given patient [11,17]. For instance,
café-au-lait spots are present within the first year of
life and cutaneous or subcutaneous neurofibromas
are usually present by adolescence [1,17,18].
The purpose of this study was to identify clinical char-
acteristics associated with internal neurofibromas in
children with NF1. Such clinical characteristics could
serve to ensure the early identification of children with
NF1 who require particularly close monitoring for in-
ternal neurofibromas.
Patients and methods
Population and study samples
The study was performed using data from two NF1
populations, one in France and the other in North
America. Patients meeting the diagnostic criteria for
NF1 established at the National Institutes of Health
Consensus Development Conference [19] were included
prospectively by the NF-France network (Réseau NF-
France) from 2002 to 2005 [20] and the Neurofibroma-
tosis Institute Database (NFID) from 1977 to 1996 [4].
The NF-France database was a French Clinical Research
Program entitled “Study of expressivity of neurofibroma-
tosis-1: constitution of a phenotype-genotype database”
[20]. The NFID is a collaborative system for collecting
demographic information, clinical signs and symptoms,
basic measurements, and psychosocial assessments of
individuals and families with neurofibromatosis [4]. The
NF-France database included 1083 patients and the
NFID 703 patients. For the present study, patients were
eligible if they were younger than 17 years of age and
had undergone imaging studies to look for internal
neurofibromas because of symptoms such as pain or
neurologic deficits or when there was evidence of in-
ternal neurofibromas on other imaging studies (Figure 1).
In all, 357 children met these criteria.
The study was approved by the Île-de-France IX Ethics
committee Paris, France. Informed consent was obtained
from all patients. The study adhered to Declaration of
Helsinki guidelines.
Data collection
The demographic information (age, sex, and whether the
NF1 was familial or sporadic) and clinical characteristics
recorded in the databases were collected during routine
clinical assessments at neurofibromatosis clinics (Table 1).
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Among the clinical characteristics, we selected those
known to be associated with mortality in children
with NF1 (plexiform neurofibromas) or showing
trends toward an association with mortality in NF1
patients (subcutaneous neurofibromas, absence of cu-
taneous neurofibromas, and short stature) [21]. Spe-
cial attention was also given to clinical characteristics
independently associated with internal neurofibromas
in adult NF1 patients, namely, fewer than 6 café-au-lait
spots, age ≤30 years (a criterion met by all our patients),
and subcutaneous and cutaneous neurofibromas [16].
Most of the other clinical characteristics selected for our
study were easily identified by physical examination, with
the exception of Lisch nodules, which were evaluated by
slit lamp examination. Detailed information was available
on the dermatological characteristics, namely, freckles,
plexiform neurofibromas, and xanthogranulomas (previ-
ous or current diagnosis). We recorded the following
characteristics as present or absent: facial asymmetry,
orthopedic complications (nonunion, dysplasia), hyperten-
sion, and macrocephaly.
Study definitions
Cutaneous neurofibromas are exophytic tumors that
move with the skin on examination [4]. Subcutaneous
neurofibromas lie deeper in the skin, do not move with
the skin, and are firm and sometimes tender to palpation
[4]. A plexiform neurofibroma is an area of thick hyper-
trophic skin with tissue hyperpigmentation overlying a
subcutaneous tumor [4]. Xanthogranulomas are soft,
flat, yellow-to-pink papules. Macrocephaly was defined
as a head circumference 2 SDs or more above the age-
and sex-matched population mean. Short stature was
defined as a height 2 SDs or more below the age- and
sex-matched population mean.
Classification of patients: identification of internal
neurofibromas
All the study patients had been evaluated for internal
neurofibromas using computed tomography (CT) and/or
NF1 patients included in the 
Réseau NF-France, n=1083
Patients 17 years or older 
n=732
Patients younger than 17 years 
n=351
Internal NF status known n=115
Internal NF status unknown
n=236
NF1 patients included in the 
NFID, n=703
Patients 17 years or older 
n=289
Patients younger than 17 years 
n=405
Internal NF status known n=242
Internal NF status unknown
n=163
357 children with NF1
Figure 1 Flow chart.
Table 1 General characteristics of the 357 children with
neurofibromatosis-1 included in the study
Clinical characteristics (n = missing data) n (%)
Male gender 192 (53.8)
Age at the first visit in years, mean ± SD (range) 7.7 ± 5.0 (0.01-16.9)
Familial case 183 (51.3)
Internal neurofibromas 35 (9.8)
Subcutaneous neurofibromas (n = 17) 72 (20.2)
Cutaneous neurofibromas 153 (42.9)
Plexiform neurofibromas (n = 184) 83 (23.3)
Café-au-lait spots 354 (99.2)
Freckles (n = 11) 219 (61.3)
Lisch nodules (n = 84) 160 (44.8)
Xanthogranulomas (n = 68) 14 (3.9)
Short stature (n = 32) 36 (10.1)
Macrocephaly (n = 21) 85 (23.8)
Nonunion 13 (3.6)
Dysplasia (n = 8) 31 (8.7)
Facial asymmetry (n = 72) 23 (6.4)
Hypertension (n = 28) 3 (0.8)
The data are number (%) unless otherwise specified.
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magnetic resonance imaging (MRI). The presence of in-
ternal neurofibromas was coded 1 in the databases.
Statistical analysis
Quantitative variables are described as mean ± standard
deviation (SD). Age was not converted to a categorical
variable. Qualitative variables are described as number
(%). All tests were two-tailed and P values <0.05 were
considered statistically significant.
The characteristics of patients with and without in-
ternal neurofibromas were compared in univariate ana-
lyses. Odds ratios (ORs) were estimated with their 95%
confidence intervals (95% CIs), using logistic regression
models. ORs were adjusted for age because the preva-
lence of several NF1 characteristics varies with age
(number of café-au-lait spots and cutaneous and sub-
cutaneous neurofibromas). Potential interactions were
assessed by pairwise analyses and confounding by fitting
multiplicative models. Variables yielding P values smaller
than 0.15 in the univariate analyses were entered into a
multiple logistic regression model. The final model
included the variables independently associated with the
presence of internal neurofibromas.
We first conducted an analysis without the individuals
who had missing data (complete-case analysis). We then
estimated the missing values for the co-variates independ-
ently associated with the internal neurofibromas in the final
model, using the multiple-multivariate-imputations-by-
chained-equations procedure in STATA [22], with the
missing-at-random assumption. We used all predictors to-
gether to impute the missing data values, and we independ-
ently analyzed 10 copies of the data using 10 cycles of
regression. Logistic regression for binary variables and
multinomial logistic regression for categorical variables with
k>2 classes were used to impute missing values.
We conducted all statistical analysis using STATA
Statistical Software (version 11.0, StataCorp LP, College
Station, TX, USA) and LogXact-8 software (2007,
CYTEL Inc. Cambridge, MA, USA).
Results
Study population
Table 1 reports the main characteristics of the 357 chil-
dren with NF1 included in our study. Mean age was 7.7
(±5.0) years (range, 0.01-16.9), and there were 192
(53.8%) males. Internal neurofibromas were present in
35 (9.8%) patients. The prevalence of internal neuro-
fibromas increased during adolescence (Figure 2). In-
ternal neurofibromas developed earlier in females than
in males (Figure 3).
Characteristics associated with internal neurofibromas
Table 2 compares the clinical characteristics in the patients
with and without internal neurofibromas. By univariate
analysis, five variables were associated or nearly associated
with internal neurofibromas: age (continuous variable), sub-
cutaneous neurofibromas, plexiform neurofibromas, Lisch
nodules, and xanthogranulomas.
The presence of Lisch nodules was strongly associated
with the other variables and was not independently asso-
ciated with internal neurofibromas in the multivariate ana-
lysis. The study of potential interactions between variables
showed a effect modification between plexiform neuro-
fibromas and subcutaneous neurofibromas (P=0.10). To
facilitate the interpretation of the model, the usual assess-
ment of interaction effects is done by entering an add-
itional variable composed of the product of the two
variables [23]. So, we replaced the interaction term by a
composite variable: no subcutaneous and no plexiform
neurofibromas (reference category), either subcutaneous or
plexiform neurofibromas, and both subcutaneous and
plexiform neurofibromas. We chose these three categories
because subcutaneous and plexiform neurofibromas had
closely similar OR values by univariate analysis (Table 2).
By multivariate analysis, three characteristics were in-
dependently associated with internal neurofibromas: age,
presence of xanthogranulomas and presence of both
subcutaneous and plexiform neurofibromas (Table 3).
The general pattern of the results after multiple imput-
ation was similar to that obtained in the patient subset
with complete data (Table 3). P values were smaller for
all three variables independently associated with internal
neurofibromas. The OR for the presence of subcutane-
ous or plexiform neurofibromas was similar between the
complete-case and imputed models. The bound categor-
ies were thinner as the multivariate analysis included all
cases after multiple imputation.
Discussion
In this study, we identified easily recognizable clinical
characteristics associated with internal neurofibromas in
children with NF1. By multivariate analysis, age, xantho-
granulomas, and presence of both subcutaneous and
plexiform neurofibromas were independently associated
with internal neurofibromas.
NF1 has been reported to be associated with a 15-year
decrease in life expectancy [2]. We recently reported
overall excess mortality in a cohort of 1895 patients with
NF1 compared to the general population in France [3].
Excess mortality occurred among NF1 patients aged 10
to 20 years (Standard Mortality Ratio, SMR, 5.2; 95% CI,
2.6-9.3; P < 10-4) and 20 to 40 years (SMR, 4.1; 95% CI,
2.8-5.8; P < 10-4). MPNSTs were the main cause of death
(60%) [3]. Thus, the main concern in the long-term clin-
ical management of patients with NF-1 is the identifica-
tion of patients at high risk for MPNSTs developed from
preexisting internal neurofibromas [2]. Although no ef-
fective treatment is available for inoperable MPNSTs,
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several novel targeted treatments may hold promise [20].
We therefore developed a clinical score, the NF1Score,
for predicting the presence of internal neurofibromas in
adults with NF1 [16].
Internal neurofibromas grow faster in young children
than in adults [15]. Volumetric MRI has been used to
assess the growth rate of internal neurofibromas in 49
NF1 patients (median age, 8.3 years; range, 3.3-25) with
a median follow up of 34 months. The growth rate per
year of internal neurofibromas was significantly greater
in the younger patients (<8.3 years) than in the older
patients (21.1% versus 8.4%, P= 0.001). In addition, if ef-
fective treatments are found, they will be more likely to
prevent the growth of internal neurofibromas than to
reduce their size [24]. Therefore, the benefits will prob-
ably be greatest if the treatments are given at the time of
most rapid internal neurofibroma growth, that is, in
childhood or adolescence. Therefore, the risk factors
identified in our study will help to improve the clinical
management of children with NF1.
Many factors support the internal validity of our study.
First, all patients had a definitive diagnosis of NF1. Se-
lection bias seems unlikely, as the prevalence of NF1
characteristics were consistent with those reported pre-
viously in other populations of NF1 patients [25,26].
Our study provided a good external validation as it was
performed using two NF1 populations, from France and
North America, respectively. However, our patients were
Figure 3 Probability of having internal neurofibromas stratified by sex (females black line and males grey line).
Figure 2 Probability of having internal neurofibromas with the 95% Confidence Interval.
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recruited at hospitals and may therefore have had
greater disease severity compared to the overall NF1
population. An important strength of our study is the
accuracy of the information on internal neurofibroma
status obtained by using MRI or CT. However, the ab-
sence of routine MRI or CT in the study population may
constitute a limitation of our study. MRI or CT was per-
formed only when routine imaging studies (chest
radiograph and abdominal sonogram) or clinical symp-
toms suggested the presence of internal neurofibromas.
Half our patients did not undergo MRI or CT. This may
have resulted in verification bias. Finally, to validate the
final model, we used multiple imputation analysis to deal
with the missing values. Multiple imputations allow indi-
viduals with incomplete data to be included in analyses
and improve the validity of the results. The empirical
Table 3 Characteristics independently associated with internal neurofibromas in the multivariate analysis on complete
cases (n = 184) and after multiple imputation (n= 357)
Complete-case analysisa, n = 184 Imputed datab, n = 357
Odds ratios 95% CI† P value{ Odds ratios 95% CI* P value**
Age 1.12x 1.02-1.23 0.012 1.16x 1.07-1.27 0.001
Subcutaneous/plexiform NFs
- None 1 1
- Either subcutaneous or plexiform NFs 1.15 0.42-3.15 0.781 1.06 0.40-2.80 0.901
- Both subcutaneous and plexiform NFs 4.95 1.80-13.64 0.002 5.89 2.18-15.89 <10-4
Xanthogranuloma 4.51 0.94-21.73 0.06 6.80 1.52-30.44 0.012
aExcluding individuals with missing values.
bMissing data imputed using imputation with chain equations.
†Odds ratio with 95% confidence interval (95% CI) by logistic regression.
{ P value by logistic regression.
xOR with 95% CI giving the risk increase for a 1-year increase in age.
*Odds ratio with 95% confidence interval (95% CI) by logistic regression with multiple imputation.
** P value by logistic regression with multiple imputation.
NF neurofibroma.
Table 2 Univariate analysis of selected characteristics for associations with the presence of internal neurofibromas in
357 children with neurofibromatosis-1




n = 322 n = 35
Male gender 148 (46) 16 (46) 1.01 (0.49-2.07) 0.977
Age (years) 7.35 ± 4.87 10.67 ± 4.81 1.14a (1.07-1.23) <10-4
Familial cases 166 (51) 17 (49) 0.61 (0.29-1.27) 0.184
Subcutaneous neurofibromas (n = 305/35) 53 (17) 19 (54) 4.51 (2.13-9.55) <10-4
Cutaneous neurofibromas 139 (43) 14 (40) 0.78 (0.37-1.64) 0.512
Plexiform neurofibromas (n= 140/33) 60 (43) 19 (70) 3.60 (1.55-8.34) 0.003
Café-au-lait spots 319 (99) 35 (100) 0.81 (0.04 - ∞) 1.000
Freckles (n = 312/34) 194 (56) 13 (28) 1.09 (0.47-2.52) 0.840
Lisch nodules (n = 250/23) 151 (60) 9 (39) 0.35 (0.14–0.86) 0.05
Xanthogranulomas (n= 257/32) 10 (4) 4 (13) 6.60 (1.69-25.74) 0.007
Short stature (n = 293/32) 32 (11) 4 (13) 1.00 (0.32-3.13) 0.996
Macrocephaly (n = 302/34) 12 (35) 73 (24) 1.65 (0.76-3.54) 0.203
Nonunion 1 (3) 12 (4) 1.8 (0.3-10.2) 0.684
Dysplasia (=314/35) 27 (9) 4 (11) 1.06 (0.34-3.35) 0.914
Facial asymmetry (n = 261/24) 20 (8) 3 (12) 1.23 (0.45-6.93) 0.419
Hypertension (n = 298/31) 2 (1) 1 (3) 5.41 (0.40-73.93) 0.205
†Odds ratio with 95% confidence interval (95% CI) by logistic regression adjusted for age.
aOR with 95% CI giving the risk increase for a 1-year increase in age.
{ P value by logistic regression, Data are numbers (%) or means ± 1 standard deviation.
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rule of entering only one variable per 10 events in a
multivariate analysis model was followed [27].
Internal neurofibromas were present in 35 (9.8%)
patients, in keeping with previous data. In a study of 53
children with NF1 who underwent MRI of the entire
spine, 7 (13.2%) patients had internal spinal neurofibro-
mas [28]. In our study, older age was independently
associated with internal neurofibromas. Excess risk of
developing internal neurofibromas seems to occur be-
tween the adolescence and the age of to 30 in NF1
patients. Moreover internal neurofibromas increased
during adolescence and developed earlier in females, in
agreement with previous data [29]. Changes in steroid
hormone production may affect the NF1 phenotype.
Immunostaining studies have provided support for
this hypothesis by identifying the progesterone recep-
tor in neurofibromas [30]. Estrogen and progesterone
increased the growth rate of MPNSTs xenografts in
mice [31]. Plexiform and subcutaneous neurofibromas
were also independently associated with internal neuro-
fibromas in our study, in accordance with earlier work in
both adults and children [7,32]. In the MRI study of the
spine in children with NF1, characteristics found more
often in patients with than without internal neurofibromas
included scoliosis (71.4% vs. 30.4%), subcutaneous neuro-
fibromas (71.4% vs. 39.1%), and plexiform neurofibromas
(28.6% vs. 8.7%); none of these differences was statistically
significant, (P=0.08, P=0.22, and P= 0.17, respectively),
possibly because statistical power was limited [28]. Fur-
thermore, patients with subcutaneous neurofibromas were
at higher risk for mortality in two different NF1 popula-
tions, from France [33] and North America [21], respect-
ively. Finally, xanthogranulomas were independently
associated with internal neurofibromas in our study. NF1
children with xanthogranulomas are at increased risk for
juvenile chronic myelogenous leukemia [34]. Although it
should be noted that this study included a small number
of patients and has not been confirmed since. To our
knowledge, xanthogranulomas have not been previously
reported to be associated with internal neurofibromas.
In sum, we identified easily recognizable clinical charac-
teristics that were associated with internal neurofibromas
in children with NF1. These risk factors could be used to
ensure the early identification of NF1 patients who require
particularly close monitoring for internal neurofibromas.
In the future, this approach may allow the initiation of
treatments at the time of fastest growth of internal neuro-
fibromas, when they are most likely to be effective.
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